Brokerages Set Protara Therapeutics, Inc. (NASDAQ:TARA) Target Price at $26.25

Posted by George Bondi on Jul 17th, 2026

Protara Therapeutics, Inc. (NASDAQ:TARA – Get Free Report) has been given an average rating of “Moderate Buy” by the eight analysts that are presently covering the firm, Marketbeat reports. One research analyst has rated the stock with a sell recommendation and seven have given a buy recommendation to the company. The average twelve-month price target among brokerages that have issued a report on the stock in the last year is $26.25.

A number of analysts recently commented on TARA shares. JPMorgan Chase & Co. lowered their price objective on Protara Therapeutics from $27.00 to $26.00 and set an “overweight” rating for the company in a research report on Thursday, May 14th. HC Wainwright restated a “buy” rating on shares of Protara Therapeutics in a research report on Wednesday, May 20th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Protara Therapeutics in a research note on Wednesday, May 20th. Oppenheimer lifted their price target on shares of Protara Therapeutics from $25.00 to $28.00 and gave the stock an “outperform” rating in a research report on Wednesday, May 20th. Finally, UBS Group reissued a “buy” rating on shares of Protara Therapeutics in a research note on Wednesday, May 20th.

Check Out Our Latest Analysis on Protara Therapeutics

Protara Therapeutics Stock Performance

NASDAQ:TARA opened at $4.08 on Friday. The company has a market cap of $229.30 million, a price-to-earnings ratio of -3.04 and a beta of 1.48. The stock’s fifty day moving average price is $4.35 and its two-hundred day moving average price is $5.22. Protara Therapeutics has a 52-week low of $2.97 and a 52-week high of $7.82.

Protara Therapeutics (NASDAQ:TARA – Get Free Report) last released its earnings results on Wednesday, May 13th. The company reported ($0.31) EPS for the quarter, beating the consensus estimate of ($0.36) by $0.05. On average, equities analysts predict that Protara Therapeutics will post -1.44 EPS for the current fiscal year.

Institutional Trading of Protara Therapeutics

Several institutional investors and hedge funds have recently made changes to their positions in the business. UBS Group AG boosted its position in shares of Protara Therapeutics by 44.2% in the 4th quarter. UBS Group AG now owns 1,215,537 shares of the company’s stock worth $6,479,000 after purchasing an additional 372,463 shares during the last quarter. AIGH Capital Management LLC bought a new stake in Protara Therapeutics in the first quarter valued at about $8,454,000. Maven Securities LTD acquired a new position in Protara Therapeutics in the fourth quarter valued at about $4,022,000. Assenagon Asset Management S.A. lifted its stake in Protara Therapeutics by 84.1% in the first quarter. Assenagon Asset Management S.A. now owns 567,621 shares of the company’s stock valued at $2,957,000 after buying an additional 259,287 shares during the period. Finally, 5AM Venture Management LLC boosted its holdings in Protara Therapeutics by 71.2% during the fourth quarter. 5AM Venture Management LLC now owns 1,369,782 shares of the company’s stock worth $7,301,000 after buying an additional 569,782 shares during the last quarter. Institutional investors own 38.13% of the company’s stock.

About Protara Therapeutics

(Get Free Report)

Protara Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing novel immunotherapies for virus-driven cancers. The company’s primary areas of research include human papillomavirus (HPV)–associated malignancies, where it seeks to harness and enhance the body’s immune response to target tumor cells. Protara’s therapeutic strategy combines antigen-specific vaccination approaches with modulators of T-cell activation to improve clinical outcomes in patients with HPV-mediated disease.

Protara’s lead immunotherapy candidate is PTX-35, an investigational monoclonal antibody designed to agonize OX40, a co-stimulatory receptor on T cells.